Boston Scientific

波士顿科学公司

(NYSE: BSX)

（纽约证券交易所代码：BSX）

+

+

announced that its Europe-based subsidiary priced a public offering totaling $1.57 billion (€1.5 billion).

宣布其欧洲子公司定价的公开发行总计达15.7亿美元（15亿欧元）。

American Medical Systems Europe B.V. (AMS Europe), Boston Scientific’s wholly owned finance subsidiary, priced a public offering of €850 million aggregate principal amount of 3% notes due in 2031 and €650 million aggregate principal amount of 3.250% notes due in 2034.

美国医疗系统欧洲公司（AMS Europe），波士顿科学公司全资拥有的金融子公司，定价了一项公开发行的8.5亿欧元总额的2031年到期的3%票据和6.5亿欧元总额的2034年到期的3.250%票据。

Collectively, Marlborough, Massachusetts-based Boston Scientific said it intends to fully and unconditionally guarantee the notes.

马萨诸塞州马尔伯勒的波士顿科学公司表示，它打算全额且无条件地担保这些票据。

Boston Scientific expects the offering to close on Feb. 26, 2025, subject to customary closing conditions. It plans to use the net proceeds, together with cash on hand, to fund the repayment at maturity of certain notes belonging to AMS Europe. AMS Europe has 0.75% senior notes due on March 8, 2025..

波士顿科学公司预计此次发行将于2025年2月26日完成，但需满足惯例的交割条件。公司计划将所得净收益与手头现金一起用于偿还AMS欧洲到期的某些票据。AMS欧洲有0.75%的高级票据将于2025年3月8日到期。

The company also intends to pay accrued and unpaid interest with respect to such notes and for general corporate purposes. Those general corporate purposes may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions..

公司还打算支付与这些票据相关的应计未付利息，并用于一般公司用途。这些一般公司用途可能包括短期投资、减少短期债务、为营运资金提供资金以及潜在的未来收购等。